Biopharma Portfolio Optimization and Board Risk Analysis
Prioritize and defend a biopharma portfolio with value modeling, correlation, downside risk, stage-gate logic, scenarios, and board-ready recommendations.
Decision questions
What this solution is built to answer.
Which assets deserve scarce capital relative to the rest of the portfolio?
Where is value concentrated, correlated, or exposed to the same biological or regulatory risk?
What changes under downside, payer, delay, or competitor-entry stress scenarios?
Which programs should move from investigate to go, hold, or kill?
Capabilities
What ARiDA can run for this use case.
Portfolio value aggregation from per-asset valuation outputs.
Correlation matrices and concentration-risk views across therapeutic area, mechanism, stage, and modality.
Downside distribution analysis from Monte Carlo simulations.
Portfolio optimization under budget and risk constraints.
Framework reconciliation across GE-McKinsey, BCG, stage-gate, three-horizons, and real-options logic.
Workflow table
Named workflows and expected artifacts.
| Workflow | Role | Artifacts |
|---|---|---|
| portfolio-quickscreen | Fast triage with Go / Investigate / Hold / Kill verdicts | PORTFOLIO__TRIAGE_SUMMARY and scoring matrix |
| portfolio-optimization | Efficient frontier, scenarios, real options, and resource allocation | PORTFOLIO__BOARD_DOSSIER, stress tornado, resource heatmap |
| portfolio-strategic-prioritization | Board-grade prioritization across strategic frameworks | Strategic dossier and board recommendation |
| valuation-professional-workflow | Portfolio valuation layer | VALUATION__PORTFOLIO, correlation matrix, risk pack, professional report |
Evidence inputs
Data sources, tools, and user context.
Outputs
What the workflow should leave behind.
Deliverables
Portfolio triage table with confidence gates.
Portfolio value and downside-risk pack.
Efficient-frontier and resource-allocation visuals.
Board dossier with explicit recommendations and caveats.
Proof points
The strategy workflows include Go / Investigate / Hold / Kill language instead of forcing false certainty.
Portfolio valuation and portfolio strategy are separate but composable surfaces.
Optimization can incorporate risk constraints rather than ranking by upside only.
FAQ
Common evaluation questions.
Does portfolio optimization only rank assets?
Ranking is one output. ARiDA also stages evidence, calculates portfolio value and risk, models constraints, and produces decision artifacts for leadership review.
Can the portfolio be revisited after new data?
Yes. The platform is built around persistent sessions, files, and workflow artifacts, so follow-up runs can update the existing case rather than starting from scratch.
Related solutions
Biotech Valuation
ARiDA runs evidence-backed biotech valuation workflows across single assets, multi-asset portfolios, platforms, fundraises, real options, Monte Carlo risk, and board dossiers.
Real Options Analysis
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Competitive Intelligence
Build competitive landscapes, TPP comparisons, patent-cliff views, market-share scenarios, and response plans from live web, trial, patent, literature, and database evidence.
Related reading
How to Triage a Portfolio Into Go / Hold / Kill Decisions
Portfolio triage is painful for a reason: it forces the organization to compare stories it would rather evaluate one by one.
From Prompt to Board-Ready Dossier
A board-ready dossier is the visible edge of a research package strong enough to survive second-order questions.
Why Multi-Agent Is Only Useful If the Work Product Is Durable
Parallel agents matter only when useful work survives the run in a form another professional can inspect and reuse.